© 2013

Theranostics, Gallium-68, and Other Radionuclides

A Pathway to Personalized Diagnosis and Treatment

  • Richard P. Baum
  • Frank Rösch


  • Examines in detail the latest developments in theranostics for neuroendocrine tumors and other diseases

  • Covers a wide spectrum of topics, from radiochemistry to clinical applications

  • Focuses on gallium-68 but also considers other PET radionuclides

Conference proceedings

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 194)

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Generators

  3. Radiochemistry and Radiopharmacy

    1. Front Matter
      Pages 99-99
    2. Irina Velikyan
      Pages 101-131
    3. Cathy S. Cutler, Nripen Chanda, Ravi Shukla, Nebiat Sisay, Melchor Cantorias, Ajit Zambre et al.
      Pages 133-147
    4. Molly E. Martin, M. Sue O’Dorisio, Whitney M. Leverich, Kyle C. Kloepping, Susan A. Walsh, Michael K. Schultz
      Pages 149-175
    5. Maung Maung Saw
      Pages 177-188
    6. Raunak Varshney, Puja P. Hazari, P. Fernandez, J. Schulz, M. Allard, Anil K. Mishra
      Pages 221-256
    7. Berit Kühle, Cristina Müller, Tobias L. Ross
      Pages 257-267
    8. Sebastian Eigner, Denis R. Beckford Vera, Marco Fellner, Natalia S. Loktionova, Markus Piel, Frantisek Melichar et al.
      Pages 269-283
    9. Lathika Hoigebazar, Jae Min Jeong
      Pages 285-299
    10. Denis R. Beckford Vera, Sebastian Eigner, Katerina Eigner Henke, Rene Leyva Montaña, Frantisek Melichar, Milos Beran
      Pages 301-317
  4. Molecular Imaging Using 68Ga labeled Tracers

    1. Front Matter
      Pages 319-319

About these proceedings


This book is based on contributions presented at the 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy, which examined recent developments in theranostics – the emerging field of molecular targeting of vectors that can be used for both diagnosis and therapy, when modified accordingly. The focus of this book is on the rapidly developing research into and clinical applications of gallium-68 and other generator-produced PET radionuclides in the personalized diagnosis and treatment of neuroendocrine tumors and other diseases.  In addition, new PET radiopharmaceuticals are considered, and the latest ideas and concepts, presented. Theranostics embodies both molecular and personalized medicine. It is at the cutting edge of medicine, and the contents of this volume will be of interest to chemists, physicians, and investigators dealing with generators, PET radiochemistry, molecular imaging, and radionuclide therapy.


Gallium-68 Neuroendocrine tumors PET radiopharmaceuticals Radionuclides Theranostics

Editors and affiliations

  • Richard P. Baum
    • 1
  • Frank Rösch
    • 2
  1. 1., THERANOSTICS Center for Molecular,ENETS Center of ExcellenceBad BerkaGermany
  2. 2.Inst. KernchemieUniversität MainzMainzGermany

Bibliographic information

  • Book Title Theranostics, Gallium-68, and Other Radionuclides
  • Book Subtitle A Pathway to Personalized Diagnosis and Treatment
  • Editors Richard P. Baum
    Frank Rösch
  • Series Title Recent Results in Cancer Research
  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 2013
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Medicine Medicine (R0)
  • Hardcover ISBN 978-3-642-27993-5
  • Softcover ISBN 978-3-642-44160-8
  • eBook ISBN 978-3-642-27994-2
  • Series ISSN 0080-0015
  • Edition Number 1
  • Number of Pages XVIII, 578
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Oncology
    Nuclear Medicine
    Molecular Medicine
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology


From the reviews:

“The general themes of this book (theranostics and peptide receptor–targeted radiotherapy) derive from evolving successes in the use of generator-produced 68Ga for molecular imaging of disease. … This book is an excellent resource for investigators interested in gaining a detailed understanding of the state of the art in 68Ga and peptide receptor radionuclide therapy–based theranostics for preclinical and emerging clinical applications.” (Michael K. Schultz, The Journal of Nuclear Medicine, Vol. 54 (4), April, 2013)